Order Growth and Revenue Guidance: MEDBOT-B reported over 30 new overseas orders in 1H25, maintaining its full-year revenue growth guidance at 85%, with a 77% increase in the first half of the year.
Financial Performance and Market Outlook: The company experienced an interim net loss of RMB113 million and a decrease in gross profit margin, while domestic sales grew by 15% YoY, with expectations of achieving over 30 orders in China by 2025.
02252
$20.16+Infinity%1D
Analyst Views on 02252
Wall Street analysts forecast 02252 stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for 02252 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
Wall Street analysts forecast 02252 stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for 02252 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
0 Hold
0 Sell
Current: 20.520
Low
Averages
High
Current: 20.520
Low
Averages
High
No data
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
